Phase 1 Non-alcoholic Fatty Liver Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting
Phase 1
Effect of Insulin Lowering on Lipogenesis
ObesityInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more
Columbia University25 enrolled1 locationNCT07403604
Recruiting
Phase 1
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Insulin ResistanceNon-Alcoholic Fatty Liver DiseaseOverweight and Obesity+1 more
Columbia University32 enrolled1 locationNCT06354088
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline30 enrolled1 locationNCT07335198
Recruiting
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 1
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
NASH - Nonalcoholic SteatohepatitisNAFLD - Non-Alcoholic Fatty Liver Disease
Tasly Biopharmaceuticals Co., Ltd.32 enrolled5 locationsNCT07128797
Recruiting
Phase 1
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Type 2 Diabetes Mellitus (T2DM)Non-alcoholic Fatty Liver Disease NAFLD
1Globe Health Institute52 enrolled1 locationNCT06694935
Recruiting
Phase 1
An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease
Bird Rock Bio Inc84 enrolled3 locationsACTRN12617000133336